Other equities analysts also recently issued reports about the stock. Credit Suisse Group upped their price target on shares of GlaxoSmithKline from GBX 1,450 ($18.95) to GBX 1,600 ($20.91) and gave the company a neutral rating in a report on Thursday, July 26th. Shore Capital reiterated a buy rating on shares of GlaxoSmithKline in a report on Tuesday, August 7th. Berenberg Bank reiterated a buy rating and set a GBX 1,790 ($23.39) price target on shares of GlaxoSmithKline in a report on Thursday, August 23rd. Deutsche Bank upped their price target on shares of GlaxoSmithKline from GBX 1,420 ($18.55) to GBX 1,525 ($19.93) and gave the company a hold rating in a report on Tuesday, July 3rd. Finally, Barclays set a GBX 1,750 ($22.87) price target on shares of GlaxoSmithKline and gave the company a buy rating in a report on Tuesday, July 3rd. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of GBX 1,521.27 ($19.88).
LON:GSK traded down GBX 1.60 ($0.02) during mid-day trading on Wednesday, hitting GBX 1,509.60 ($19.73). 7,490,353 shares of the stock traded hands, compared to its average volume of 9,120,000. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($16.14) and a 52 week high of GBX 1,724.50 ($22.53).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: Insider Trading – What You Need to Know
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.